Melita Irving
Scientist
Ludwig Center at Lausanne
Ludwig Institute for Cancer Research
Switzerland
Biography
Since January 2013 I am the project leader for T cell engineering in the laboratory of Dr. George Coukos at the Lausanne Branch of the Ludwig Institute for Cancer Research, which is based at the University of Lausanne in Switzerland. I oversee a very talented, international team of post-doctoral scientists, students and technicians; together we are working to develop gene-engineered T cells and optimal combinatorial treatments for personalized immunotherapy of cancer patients.
Research Interest
Immunotherapy, tumor biology
Publications
-
Saphire, Erica Ollmann, et al. "Structure of a high-affinity “mimotope†peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies." Journal of molecular biology 369.3 (2007): 696-709.
-
Zwick, Michael B., et al. "Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12." Journal of virology 75.14 (2001): 6692-6699.
-
Irving, Melita B., Oscar Pan, and Jamie K. Scott. "Random-peptide libraries and antigen-fragment libraries for epitope mapping and the development of vaccines and diagnostics." Current opinion in chemical biology 5.3 (2001): 314-324.
